Clinical Trial Update: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating INCB001158 with subcutaneous daratumumab versus daratumumab SC alone in relapsed or refractory multiple myeloma has been terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab SC (Darzalex Faspro) (daratumumab)
• INCB001158

Snippet

Sponsor: Incyte Corporation | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-03-20